We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIP has gained about 52.6% so far this year. Meanwhile, the Medical sector has returned an average of 8.8% on a year-to-date basis. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Black Diamond (BDTX - Free Report) . The stock has returned 76.6% year-to-date.
In Black Diamond's case, the consensus EPS estimate for the current year increased 33.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 467 individual companies and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have gained about 20.4% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Black Diamond is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANI Pharmaceuticals and Black Diamond as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIP has gained about 52.6% so far this year. Meanwhile, the Medical sector has returned an average of 8.8% on a year-to-date basis. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Black Diamond (BDTX - Free Report) . The stock has returned 76.6% year-to-date.
In Black Diamond's case, the consensus EPS estimate for the current year increased 33.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 467 individual companies and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have gained about 20.4% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Black Diamond is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANI Pharmaceuticals and Black Diamond as they could maintain their solid performance.